You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma: Comparison
View Latest Version
Please note this is a comparison between Version 1 by Nuno Cruz and Version 2 by Jason Zhu.

Glioblastoma multiforme (GBM) remains a challenging disease, as it is the most common and deadly brain tumour in adults and has no curative solution and an overall short survival time. This incurability and short survival time means that, despite its rarity (average incidence of 3.2 per 100,000 persons), there has been an increased effort to try to treat this disease. Standard of care in newly diagnosed glioblastoma is maximal tumour resection followed by initial concomitant radiotherapy and temozolomide (TMZ) and then further chemotherapy with TMZ. Imaging techniques are key not only to diagnose the extent of the affected tissue but also for surgery planning and even for intraoperative use. Eligible patients may combine TMZ with tumour treating fields (TTF) therapy, which delivers low-intensity and intermediate-frequency electric fields to arrest tumour growth. Nonetheless, the blood–brain barrier (BBB) and systemic side effects are obstacles to successful chemotherapy in GBM; thus, more targeted, custom therapies such as immunotherapy and nanotechnological drug delivery systems have been undergoing research with varying degrees of success.

  • brain tumour
  • glioblastoma multiforme
  • treatment
  • imaging
  • nanotechnology
  • tumour treating fields

1. Surgery

1.1. Preoperative Techniques

The preoperative techniques here presented rely on imaging techniques to obtain anatomical and physiological data on the tumour, “mapping” the target volume by revealing tumour mass spread, and detailing its location in relation to important, eloquent brain tissue.
Magnetic resonance imaging (MRI), which uses strong magnetic fields and radio waves to excite protons and produce an image [1], is the standard method of lesion visualisation. Computed tomography (CT), a computerized X-ray imaging technique which uses narrow X-ray beams quickly rotated around the body to produce cross-sectional images, is used when MRI is not available or possible (e.g., a patient with a non-MRI-compatible pacemaker or other metallic implants) [2]. Gadolinium enhancement is a typical feature of GBM, and this imaging technique usually reveals a heterogeneous mass with a necrotic core and surrounding oedema [3][4]. Magnetic resonance spectroscopy (MRS) allows for further characterization of the lesion by visualising metabolites that can be associated with a malignant tumour, specifically an increase in choline and decrease in N-acetyl aspartate, which are associated with higher cellular turnover and lower neuronal cellularity [4][5]. It also allows primary brain tumours, radiation necrosis, and metastases to be distinguished [6].
Positron emission tomography (PET) is another imaging technique that retrieves metabolic information, as it can measure the uptake of a radioactive tracer into the tissues of interest [7]. After administration of the tracer, a biologically active molecule such as an amino acid or carbohydrate [8], and waiting for its uptake, the patient is taken to a scanner [7]. Then, as the name implies, the tracer decays, emitting positrons that annihilate themselves with electrons of the tissues, producing 511 keV photons [9]. These photons can then be detected using appropriate equipment, and an image can be produced [9][10]. In particular, 18Fluoro-O-(2) fluoroethyl-l-tyrosine([18F] FET) or FET is commonly used due to its longer half-life compared to alternatives such as Carbon-11 and due to its sensitivity and specificity to GBM; it is thus able to improve glioma identification, tumour diagnosis, and size assessment [11][12]. When combined with MRI, FET PET can allow for better evaluation of progression and response, as contrast is not affected by changes in the blood–brain barrier (BBB) that can be caused by therapy [11][13][14]. These traits mean that FET PET has prognostic value in radiotherapy planning and results in better tumour tissue delineation for surgical planning [15][16][17]. FET PET’s properties have led to interest in hybrid imaging systems, such as MR-PET. The combination of these imaging techniques improves tumour delineation compared to MRI, supplying metabolic and anatomical data invaluable to biopsy and surgical planning [18][19][20]. Minimizing intermodal interference is a main concern when designing an MR-PET system, and efforts in PET component shielding, MR magnetic field calibration, and optimization of data acquisition and image reconstruction have been made to unlock this technique’s potential [21].
Tractography is a way to analyse the brain’s white matter in 3D space [22]. It is an MRI sequence that calculates water diffusion and detects the Brownian motion of water inside cells, creating a map of white matter tracts [22][23]. This technique allows for better planning of surgery to avoid possible eloquent white matter tracts, which maximises resection and preservation of function [24]. It can be combined with preoperative blood-oxygenation-level-dependent (BOLD) functional MRI (fMRI) to complement with information on areas dedicated to speech and movement, as well as hemispheric dominance [22][23]. This combination can further increase the amount of eloquent tissue spared [24][25]. The anatomical and functional data provided by these techniques is then used to plan a surgical intervention.

1.2. Intraoperative Techniques

Medical imaging techniques are also applied during surgery: these intraoperative imaging techniques aim to assist the surgeon to achieve maximum resection while preserving eloquent areas of the brain [5][26][27]. One such technique applies a fluorescent agent called 5-aminolevulinic acid (5-ALA) to achieve a red coloration of tumour tissue under blue light stimulation (400–410 nm) [28], which allows for a greater extent of resection when compared to surgery under white light [29]. The biggest limitation of this technique is that direct visualisation of the tissue is required, so additional functional and anatomical information of the tumour is invaluable to avoid both a bad estimation of total gross resection and damage to eloquent areas [5]. An alternative but not routine technique aimed at preserving eloquent areas uses another fluorescent agent, indocyanine green (ICG), to produce videoangiography of cerebral vessels, thus allowing the surgeon to avoid injuring small calibre vessels during resection [27]. Intraoperative MRI (iMRI) is the utilization of MRI during surgery to acquire real-time, high-definition images that allow the surgeon to evaluate the extent of resection more easily via a portable device or moving the patient to a nearby iMRI room [30]. Evidence on the usefulness of iMRI is split. On one hand, there is some evidence that iMRI is helpful, as it circumvents the limitations of preoperative imaging, which does not translate anatomy as well due to brain volume distortions after craniotomy [31]. On the other hand, it is a costly technique that does not show any statistically relevant difference compared to less advanced techniques, namely 5-ALA [23][32][33]. That said, there has been some evidence that the combined use of iMRI and 5-ALA achieves the best possible results in the extent of resection without any significant increase in post-operative neurological deficits [34][35].

1.3. Pseudoprogression

Distinguishing true tumour progression (TP) from pseudoprogression (PsP) is a challenge given that medical imaging is both used in the execution and interpretation of clinical trials and in day-to-day patient evaluation [36]. Pseudoprogression usually manifests as posttreatment radiographic evidence of disease progression that can be accompanied by symptoms, which resolves or improves without additional treatment [37][38]. To improve diagnosis, both the establishment of predictive factors and improvement of imaging techniques are necessary. In a literature review by Fèvre et al. [39], the literature featuring PsP in patients treated with chemoradiation was examined to identify clinical and molecular markers to differentiate PsP from TP. They concluded that the data are discordant and that the current standard, response assessment in neuro-oncology (RANO) [40] and modified RANO [41], remains the most applicable in clinical practice. Other reviews [36][37][42][43][44] focus on MR and PET approaches to PsP in brain tumours and agree that advanced imaging techniques such as diffusion-weighted imaging, perfusion MRI, single photon emission computed tomography, and proton MRS are better at distinguishing PsP from TP than conventional MRI. However, these reviews also point out a lack of standardization of methodology for data acquisition as well as a lack of large validation studies.

1.4. Recent Advances

In the field of GBM imaging, Denora et al. [45] synthesised ultra-small iron oxide nanoparticles (USPIONs) combined with a fluorescent dye and a translocator protein (TSPO) ligand for near-infrared (NIR) imaging. TSPO is overexpressed in several cancer types, including gliomas. The system showed no toxicity in vitro, and selective targeting of the nanoparticles to TSPO was confirmed both in vitro and in a murine xenograft model [45]. Henderson et al. [46] explored the potential role of desorption electrospray ionisation mass spectrometry (DESI-MS) for ex vivo sample analysis. They constructed 3D DESI-MS images by combining the 2D data, which allowed them to obtain a 3D representation of the sample that evidenced its metabolic heterogeneity. They posit that this method of automated 3D DESI-MS acquisition can increase throughput for larger amounts of samples and provide important information about GBM responses to its microenvironment and hypoxia [46].
Recent advances in PsP identification include work by Sun et al. [47], who used a machine learning strategy combined with radiomic features from T1-weighted contrast-enhanced imaging to differentiate PsP from TP. GBM patients that underwent total or subtotal resection and chemoradiotherapy and were confirmed via second surgery or radiological follow-up to exhibit either TP or PsP made up the training population. Volume of interest was determined separately by two experienced (10+ years of experience) neuroradiologists, with a third senior (25 years of experience) neuroradiologist resolving inconsistencies between their determinations.
Other studies investigated additional techniques that go beyond the use of imaging and approach the surgical procedure itself. Gerritsen and colleagues [48] investigated the use of awake craniotomy, where the patient is kept awake so cortical mapping of eloquent structures can be made, versus surgery under general anaesthesia. Researchers found that for low-grade glioma, awake craniotomy resulted in greater resection, lower neurological complications, and better quality of life for patients, with recent results for GBM also appearing promising. Dimou et al. [49] conducted a systematic review of the effects of supramaximal resection, where the surgeon removes tissue beyond the T1-enhancement area provided by MRI, to tackle GBM’s ability to spread microscopically beyond the macroscopically observable border. However, no strong evidence towards the usefulness of this technique was found in their analysis. Bettag et al. [50] studied the use of an endoscope to induce fluorescence in 5-ALA fluorescence-guided resection, which allows a surgeon to observe the target tissue without needing direct line of sight. They administered a standard dose of 5-ALA (20 mg/kg) and used a prototype endoscope to scan for any remaining fluorescent tissue after normal fluorescence-guided resection; they achieved an increase in resection rate from 65% to 95%, although the study was limited by the small sample of twenty patients.

2. Chemotherapy

2.1. Standard of Care

After maximal resection of the cancerous mass, the next treatment involves concomitant radio and chemotherapy. The standard of care is a 60 Gray (Gy) dose of radiation, fractionated in portions of 2 Gy, with daily administration of temozolomide (TMZ) at 75 mg/m2 during radiotherapy, followed by six maintenance cycles of 150 to 200 mg/m2 of TMZ for 5 days every 28 days [51][52][53]. TMZ is an alkylating agent that is administered orally, which works by alkylating/methylating guanine residues in DNA, thus leading to tumoral cytotoxicity through cell cycle arrest [26][54]. A 5-year study of the effects of TMZ on overall survival (OS) of GBM patients found a significant increase compared to radiotherapy alone: from 10.9 to 27.2% 2-year survival [55]. However, TMZ is limited in its action due to GBM’s capability to develop resistance to the drug. Basically, if tumour cells retain their ability to repair the damage done by methylation of DNA, they can overcome TMZ treatment [56]. One such repair mechanism is regulated by MGMT, a DNA repair enzyme, and it has been shown that patients with a methylated MGMT promoter gene had a better prognostic and OS than patients with the non-methylated MGMT promoter gene [55][56][57].
Another drug used in GBM treatment is carmustine. It is a nitrosourea with alkylating and BBB-crossing capabilities [58]. It is usually administered in a polymeric wafer (carmustine wafers, CW) implanted after tumour resection. [4][54][59]. This local administration of carmustine greatly reduces the severe toxic effects of the drug, namely bone marrow suppression, hematotoxicity, hepatotoxicity, nephrotoxicity, and pulmonary fibrosis. Such toxicity is the reason why carmustine use was avoided after the introduction of TMZ to the treatment of GBM by the Food and Drug Administration (FDA) in 1999 [60]. Such delivery of the drug as CW allows for a 100-fold increase in the local concentration without the systemic side effects of intravenous administration [61]. Nonetheless, the use of CW remains controversial due to the drug’s toxicity, the potential for adverse side effects, and post-surgery complications and infections in the case of wafer usage, though recent studies show an increase of median survival to about 17 months [62][63].
Bevacizumab, like carmustine and TMZ, is an FDA-approved chemotherapeutic agent for the treatment of GBM, which has been used since 2006. It consists of a monoclonal antibody that targets the vascular endothelial growth factor (VEGF) ligand, thus inhibiting tumour-driven angiogenesis [54][57]. When administered in conjunction with the standard-of-care treatment, bevacizumab increases progression-free survival (PFS) but not OS [26][54][64][65]. The main adverse side effects are arterial hypertension, although there are other rarer but serious effects such as haemorrhages, thromboembolic events, complications of wound healing, congestive heart failure, and gastrointestinal perforations [2][3]. The 2022 ASCO-SNO guideline does not consider bevacizumab’s benefits to outweigh the harms, so this drug is no longer recommended for GBM treatment [66]. Nonetheless, the EANO guidelines recognize bevacizumab as an option for recurrent disease and symptomatic patients with large tumours, although it is not approved for patients in the European Union [67].

2.2. Nanomedicine in GBM Chemotherapy

To overcome both the physical barrier to treatment that is the BBB and to reduce side effects from treatment, nanotechnology has been applied in drug delivery. Nanotechnological drug delivery systems have seen use in different applications from dermo-cosmetic, to wound healing, and therapies such as photodynamic therapy (PDT) [68][69][70][71]. Recent efforts in GBM chemotherapy include work from Guo et al., where a thiolated paclitaxel-oligo (p-phenylene vinylene) nanomedicine was designed [72]. The authors suggested that this nanocarrier was able both to cross the BBB (10% BBB penetration) and form aggregates around the tumour, thus reducing payload escape from the target tissue. This nanocarrier led to at least 3% more apoptosis of U87MG and U343 GBM lines when compared to free paclitaxel (PTX). Moreover, selective retention on GBM since the first hour of treatment was observed, and it remained on GBM tissue even after seven days. Moreover, the in vivo inhibition of GBM exceeded 50%, which is greater than the 26% inhibition rate of free PTX, and it did not induce any weight loss.
Another successful example was published by Ferreira et al. [73]. They designed chitosan-poly(lactic-co-glycolic acid) (chitosan-PLGA) nanoparticles with mucoadhesive properties for nose-to-brain delivery of chemotherapy (alpha-cyano-4-hydroxycinnamic acid (CHC) and the monoclonal antibody cetuximab (CTX)), thus bypassing the BBB. These particles were stable for up to 3 months and would only induce cytotoxicity when carrying the therapeutic agent. Their mucoadhesive particles were stable, with a positive surface charge (+37 mV) and a high entrapment efficiency (>75%). The chitosan-PLGA nanoparticles themselves did not incur any in vitro cytotoxic activity when loaded with CHC and surface functionalized with CTX. They dropped cell viability of human astrocytoma model SW1088 and human glioblastoma model U251 to around 5%.
Zheng et al., designed a self-assembling protein structure of haemoglobin and glucose oxidase encapsulated by a red blood cell membrane [74]. This biocompatible nanosystem was found to be capable of crossing the BBB and accumulating at the tumour site, thus generating anti-tumour activity via reactive oxygen species (ROS). The nanosystem exhibited high in vitro cytotoxicity towards the GBM cell line U87MG and murine fibroblast NIH-3T3 cells but only when glucose was present to allow for ROS production; it dropped cell viability to around 20%. In vivo studies also confirmed BBB crossing and passive targeting of cancer tissue; 12 h after intravenous administration of ICG-loaded nanoparticles, fluorescence in brain tissue was evident. After 72 h, this fluorescent signal remained in the brain, whereas it was absent in other major organs. Furthermore, treatment supressed tumour growth in mice and induced apoptosis of cancer tissue.
Saha et al., designed amphetamine lipid nanoparticles, exploiting the innate capabilities of amphetamines to cross the BBB [75]. These loaded nanoparticles were not only non-cytotoxic but also showed preferential accumulation in the brain and were able to encapsulate PTX and programmed death-ligand 1-small interfering RNA (PDL1-siRNA), two anti-glioma drugs. Controlled release of PTX was also achieved after 25 h, with the release at physiological pH being lower (<60%) than at a pH of 5 (>80%). In vitro cell viability studies also showed that cytotoxicity towards non-tumoral model Chinese hamster ovary cells of PTX-loaded nanoparticles was around 20%, whereas against the GBM cell line GL261, it ranged from 50 to 70% after 24 h.
Manju and colleagues [76] produced a multi-gene-targeted siRNA nanoparticle gel (NPG) for intracranial injection. The genes targeted were FAK, NOTCH-1, and SOX-2 expressed in glioma stem cells (GSCs). The gel was prepared by the self-assembly of siRNA with a protamine–hyaluronic acid combination, resulting in siRNA nanoparticles with an average size of 250 nm as determined by dynamic light scattering (DLS) and 95% loading efficiency as determined by agarose gel electrophoresis. The group justified the triple gene targeting with these genes’ inter-regulation, which makes single-gene-targeting therapy insufficient. In vitro, rat glioma neurosphere formation after 14 days was suppressed by 90% compared to untreated cells and compared to 20% suppression for TMZ-treated cells. Furthermore, for human GBM neurospheres, TMZ did not supress neurosphere formation, whereas NPG-treated cells achieved over 90% suppression. In vivo, in a patient-derived xenograft model, the treated group was administered NPG at the date of tumour transplant (day seven), which showed no significant tumour growth after 120 days, as confirmed through MRI. The control recorded tumour volume was 2.5 cm3 by day 30, and TMZ-treated rats exhibited 1.5 cm3 tumour volumes. Most importantly, intracranial administration of NPG in a rat orthotopic tumour model (1.9 mm3 tumour volume confirmed by MRI) exhibited no tumour growth up to 120 days after a single dose.

3. Radiotherapy

As mentioned in the previous section, the standard of care after maximal resection is concomitant fractionated RT (60 Gy given in fractions of 2 Gy over 6 weeks) with TMZ [54]. RT achieves its therapeutic action by damaging tumour cells’ DNA and creating free radicals via ionizing radiation [77][78]. However, GBM is capable of recurrence after therapy, with the possibility of developing resistance to RT [78][79]. Nonetheless, different strategies for GBM RT exist, from typical 3D conformal RT, where X-rays are delivered to the target volume from different angles to spare non-malignant tissue, to stereotactic radiosurgery (SRS), where focused beams achieve more precise targeting than 3D conformal RT but are limited to smaller volumes and require patient immobilization, or brachytherapy, where radioactive vectors are implanted into the tumour bed [80][81]. Proton therapy (PT) or proton beam radiation therapy (PBRT) is yet another strategy that utilizes protons instead of photons for focused energy delivery to target volume, exploiting the faster deceleration of protons. This allows for limited off-target doses compared to photon RT [82].
Recent advances include a phase II trial published by Mohan et al. [83], where they investigated the effect of proton vs. photon radiotherapy in radiation-induced grade 3+ lymphopenia (G3 + L). Both arms in this randomized trial were treated with concomitant TMZ and had their absolute lymphocyte count (ALC) measured before, during, and up to 1 month after treatment. Researchers found that males and individuals treated with PT had lower incidence of G3 + L (15 and 14%, respectively) versus X-ray radiotherapy (XRT) (39%) and that individuals treated with PT had a lower whole-brain mean dose (WBMD) (20.1 ± 5.7 Gy) compared to XRT (27.0 ± 6.1 Gy).
In another phase II trial involving PT [84], Brown and colleagues compared time to cognitive failure of patients treated with intensity-modulated radiotherapy (IMRT), an XRT modality where increased 3D conformity is achieved via several modulated beams with different intensities, at different angles, versus PT. All patients were newly diagnosed with GBM and randomized unblinded 1:1 to each group. The primary endpoint was time to cognitive failure, with secondary endpoints being overall survival (OS), intracranial progression-free survival (PFS), toxicity, and patient-reported outcomes (PROs). The study found there was no statistical difference in OS (median 21.2 months in IMRT vs. 24.5 months in PT), PFS (8.9 months in IMRT vs. 6.6 months in PT), or rates of deterioration between the two arms at 6 months. There was a reduction in mean number of toxicities (1.15 IMRT vs. 0.35 PT) and patient reported fatigue (58% IMRT vs. 24% PT). The study was limited by its sample size and the number of patients from the PT arm that were denied treatment by their insurance, which further reduced the size of the arm.

4. Immunotherapy

By a very short definition, cancer immunotherapy is the activation of the immune system to fight cancer cells, and it has been used against melanoma, prostate, and lung cancers, among others [85]. There are several approaches to immunotherapy, from vaccination, which exposes the immune system to tumour-specific antigens; to adoptive cell therapy (ACT), where specific antigen receptors are introduced into T cells, creating T cells specifically capable of targeting tumour cells; the inhibition of tumour immunosuppressants (check-point inhibition); and the stimulation of the immune system with cytokines such as interleukine-2 (IL-2) [54]. The biggest hurdle that must be overcome for GBM immunotherapy is its capability to avoid the immune response [64][86][87]. Low T cell infiltration due to the BBB, no lymphatic drainage, low antigen presentation, and high heterogeneity all facilitate its immune evasion [64][88][89]. Furthermore, it has been found that GBM patients tend to exhibit an increased Treg (an immunosuppressant T cell) population, and the glioma itself has the ability to produce and secrete immunosuppressants and immune response downregulators such as interleukin-10 (IL-10) and indoleamine-pyrrole 2,3-dioxygenase (IDO) [87]. These difficulties mean that there is no standard-of-care immunotherapy for GBM yet.
A systematic review by Marenco-Hillembrand et al., in 2020 found that cancer-vaccine-based immunotherapy has shown median OS increases, though only dendritic vaccines were able to provide any significant increase, albeit a marginal increase, when compared to the standard of care [90]. Youssef and colleagues reviewed the role of Ipilimumab in GBM immunotherapy. Ipilimumab is a monoclonal antibody that targets the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint, a downregulator of the immune response that is currently used to treat skin, prostate, and lung cancers. In a different point of view, the use of viral vectors to either deliver a genetic payload or selectively lyse tumour cells has also seen important developments with Ofranergene obadenovec (VB-111) in combination with bevacizumab. A phase III trial compared this combination against bevacizumab monotherapy. However, no statistically significant improvement in OS was observed [91]. Another phase III study, with the programmed cell death protein 1 (PD-1) immune checkpoint blockade nivolumab showed no statistical difference in OS when compared with bevacizumab [92]. Haddad et al., attributed the contrast between the successes in preclinical trials and the failures in later phase clinical trials to the difficulty of creating a model that allows for a holistic representation of the immune system’s response to GBM [93].
In recent developments, Wang et al. [94] produced a pH-sensitive BBB-crossing protein delivery and release system for anti-PD-L1 (programmed death ligand 1). The nanosystem relies on the choline analogue, 2-methacryloyloxyethyl phosphorylcholine (MPC), polymerized with short-chained poly(ethylene-glycol) methacrylate (PEGMA) to form a precursor, which is then conjugated with anti-PD-L1 via the pH-sensitive linker 3-(bromomethyl)-4-methyl-2,5-furandione. This choline analogue system targets the choline transporter expressed on the endothelial cells that constitute the BBB, and the pH-sensitive component releases the anti-PD-L1 in the acidic tumour environment. The group obtained spherical particles with sizes under 100 nm, which are stable in cell culture medium solutions. In a BBB in vitro model, a maximum 4 h penetration efficiency of 12% was achieved. In vitro cytotoxicity towards both the endothelial cell line bEnd.3 and murine glioma LCPN was found to be negligible. In vivo, the LCPN murine glioma animal model was used to evaluate BBB crossing, pharmacokinetics, and therapeutic effect. The system was able to reach the subjects’ brains after intravenous administration, and it targeted the tumour and extended morbidity-free survival in comparison to the untreated mice (16 days treated vs. 6 days untreated); it did not cause any obvious histological damage to major organs (kidney, spleen, liver, heart, or lung). A comparative study with a TMZ-treated control is, nonetheless, still necessary to evaluate performance against standard-of-care chemotherapy.
Todo et al. [95] conducted a single-arm phase II trial to test the effectiveness of intratumoural oncolytic herpes virus G47∆ for residual or recurrent GBM treatment. For nineteen patients with recurrent or residual GBM after treatment with surgery, TMZ and RT were selected and were administered G47∆ during stereotactic surgery. The maximum number of administrations was six and was limited by tumour progression. Median OS was 20.2 months and PFS was 4.7 months, which compare favourably with other treatments for recurrent GBM. All patients suffered from adverse effects related to immune responses, with more severe cases being managed with corticosteroids. These adverse effects were considered safe, and combined with the performance in this trial, G47∆ was approved in Japan on 11 June 2021, thus becoming the first oncolytic drug in Japan.
Overall, although immunotherapy promises to deliver a very custom and targeted therapy to GBM, it has not yet delivered in late phase trials. There is still a lot of work to be done to overcome the immunosuppression hurdles that GBM presents and in developing preclinical models that more closely resemble the patients’ realities. Studies such as that by Todo et al., seem to be a potential step forward in creating a standard-of-care immunotherapy, but larger studies are necessary.

5. Tumour Treating Fields

TTF were approved by the FDA for treatment of recurrent GBM in 2011 (and for newly diagnosed GBM alongside TMZ in 2015) using low intensity (1–3 V/cm) and intermediate frequency (100–500 kHz) alternating electrical fields [3][57]. The new ASCO-NSO guideline recommends TTF therapy for newly diagnosed supratentorial glioblastoma after completing chemoradiation therapy [66]. The goal is to disrupt the cell cycle and halt cancer cell proliferation while not disturbing the normal functioning of quiescent cells [3][57]. These alternating electrical fields have since become standard of care in the United States, combined with surgery, radiotherapy, and chemotherapy [64]. This therapy results in increased OS without reducing quality of life, and adverse side effects are limited to skin reactions [26][54][57][96][97]. In practice, this treatment involves wearing on the shaved scalp a portable, patient-operated device with four transducer arrays for 18 h every day [65]. Normal proliferation of cancer cells gradually recovers after exposure to the TTF stops, hence the 18 h daily treatment duration [98]. The mechanism of action of TTF is based on the fact that the molecules and structures involved in cell division are highly polar and, as such, susceptible to applied electrical fields [99]. This means that, during metaphase, the formation of a functioning mitotic spindle is disturbed; during telophase, normal cytokinesis is disrupted; and during anaphase and telophase, the cellular shape combined with the field leads polar molecules to migrate towards the narrow furrow, thus disrupting the cell membrane [54][64][97][98][99].
This system is not without limitations; its cost is about $180,000 annually per patient [26][64][100]. Furthermore, most patients do not see their OS increase beyond 2 years [26]. Moreover, the efficacy of treatment is directly tied to patient compliance since treatment must be sustained and patient-operated [101]. To maximize the effectiveness and increase understanding of this treatment, there have been ongoing efforts to characterize TTF [102] with the aim of personalized care [103] and to augment the exposure of tumour areas to therapeutic doses of TTF via personalized array distributions [104]. There are also efforts to further optimizing the equipment’s running temperature for increased quality of life for the patient [105]. Nonetheless, according to EANO guidelines, the usage of this treatment modality remains controversial in its cost-effectiveness and feasibility as a standard of care, and, as such, it has seen reduced adoption [67]. Furthermore, these guidelines argue that the clinical benefit of TTF has not been established yet, which contradicts the ASCO-NSO guidelines and does not recommend this line of treatment in post-chemoradiation-therapy patient maintenance [67].

6. Photothermal and Photodynamic Therapy

Photothermal therapy (PTT) and PDT are treatments that rely on light sources, typically lasers, to achieve their effects [106][107]. In PTT, an NIR laser irradiates a tumour topically or through an optic fibre probe, which excites a photoabsorbing agent (PTA). This agent converts the irradiated light into heat, creating a localized hyperthermal effect that triggers cell death [106][108]. Depending on the target temperature, cell death might be triggered by thermal ablation (45 °C), or cellular damage and tumour permeability (42–43 °C) via protein denaturation and disruption of cellular membranes [109][110]. The materials for PTAs vary from metallic nanostructures of gold and copper to carbon and graphene nanostructures, polymer nanoparticles, and so on; they are sensitive to different laser wavelengths [111][112][113]. PTT can be associated with unwanted damage to surrounding healthy tissues, but delimitation of the light beam can be achieved via optical systems or blocking with insulating materials, such as aerogels [114].
A concrete example of PTT usage is magnetic resonance-guided laser-induced thermal therapy (MRgLITT or LITT), with systems like Visualase or NeuroBlate [100]. In these minimally invasive systems, MRI is used to localise the tumour, and then an NIR laser is transmitted via optic fibres to the target tissue, thus heating it to a target temperature of 43 °C [100][115]. MR thermography allows for real-time evaluation of temperature changes and ablation [115][116]. Treatment can still incur thermal damage to critical and eloquent brain tissue even with MRI guidance [116]; however, with proper training, it has potential to provide comparable survival to open surgery in recurring disease and provide a tumour removal option to patients’ ineligible for surgery [115][117][118][119].
Recently, results from a single-arm clinical trial (NCT03020017) [120] utilizing spherical nucleic acid (SNA) gold nanoparticles targeting the oncogene BCL2L12 (B cell lymphoma 2-like 12) in recurrent GBM were released. Eight adult patients with recurrent GBM were treated with intravenous administration of these particles (named NU-0129), followed by tumour resection. NU-0129 was found to reach the tumour, incorporate into glioma cells, and induce reduction in BCL2L12 protein expression. Nicole et al. [121] studied Prussian blue nanoparticles (PBNPs) conjugated with anti-fibroblast growth factor inducible 14 (anti-Fn14) for targeted photothermal therapy for GBM. Since Fn14 is a receptor abundantly expressed on many glioblastomas but near absent on healthy CNS tissue, the authors aimed to avoid off-target effects of PTT by targeting this receptor with their system. The conjugated system maintained its stability for at least 21 days, and in vitro PTT of U87MG and U251 resulted in reduction of cell viability from 97.85% to 18.45% and 95.00% to 11.19%, respectively. Furthermore, anti-Fn14-PBNPs exhibited higher cell attachment when the particles were incubated with U87MG cells, whereas simple PBNPs did not. In vivo tests were not conducted and are necessary to confirm targeted therapy in a live model.
In PDT light is used to activate a photosensitizer (PS) molecule responsible for the creation of ROS, which react with the macromolecules that constitute cell and organelle membranes, thus damaging these structures and inducing cell death [107][122]. It is oxygen dependent, meaning that adequate tissue oxygenation is necessary to achieve therapeutic effects [123]. As in PTT, NIR light has deep penetration and higher safety compared to shorter wavelengths that can be used, and PS drugs are also varied and include organic and inorganic nanostructures. These can be sensitive to specific wavelengths, include molecules that increase tissue oxygenation (e.g., catalase and haemoglobin), and can be functionalized with ligands higher for tumour tissue specificity [109]. Recently, Silva and colleagues [124] developed X-ray-absorbing scintillating europium-doped gadolinium oxide nanoparticles. Their goal was to create particles capable of converting X-ray radiation to ultraviolet-visible (UV-Vis) light for more efficient activation of PS. Both gadolinium oxide and hybrid silica and gadolinium oxide nanoparticles agglomerated in aqueous solution; however, they exhibited low to no toxicity in vitro, and were capable of converting X-rays to light in the UV-Vis range. Schipmann et al. [125] tested the use of 5-ALA, a fluorescent agent used for fluorescence-guided resection, as a PS precursor for PDT for recurrent high-grade glioma treatment. After removal of non-eloquent fluorescent tissue, diffusors were introduced in the cavity for laser irradiation of the remaining tissue (635 nm, 200 mW/cm diffusor). The combined regimen did not result in adverse events or new neurological deficits, and it delivered favourable PFS. However, a small sample size, retrospective design of the study, and difficulty in evaluating the effect of PDT in post-op MRI were limitations that warrant further studies to confirm their method’s viability.

7. Magnetic Thermotherapy

Like PTT, magnetic thermotherapy aims to induce localised cell death via an increase in temperature, either in hyperthermia or ablation ranges [126]. This is achieved via injection of superparamagnetic iron oxide nanoparticles (SPIONs) into the target tissue and exposure to an alternating magnetic field (AMF) [127][128]. Besides the more obvious impact in tissue disruption or ablation, enhanced infiltration of natural killer (NK) cells, T cells, dendritic cells, and macrophages into necrotic areas has been observed in preclinical glioma models [129]. Hyperthermia was also seen to induce an immune response chaperoned by heat shock protein (HSP)-peptide complexes released by dying glioma cells [130] These proteins are overexpressed in gliomas and are possible targets of inhibitors for hyperthermia sensitization; moreover, their release by dying cells stimulates T cell responses [129][130][131]. As in PTT, particle characteristics such as core size, composition, shape, and surface shell can be tailored to the application, and, as such, there have been systems designed for synergistic strategies with radio-, chemo-, and immunotherapy [126][128][129][132].
Recent studies include the work by Minaei and colleagues [133], where theragnostic folic-acid-conjugated TMZ-loaded SPION@poly(ethylene glycol)–poly(butylene adipate)–poly(ethylene glycol) (PEG-PBA-PEG) nanoparticles (TMZ-MNP-FA NPs) were synthesized to use as MRI contrast agents and enhance hyperthermia and radiotherapy. Particles exhibited a spherical shape, low polydispersity (PdI = 0.26), and a maximum size under 50 nm. TMZ release was pH dependant, increasing release at lower pH typical of tumour environments, and the system was capable of increasing temperature of solutions in a concentration-dependant fashion. Irradiation with AMF also increased the release rate of TMZ (6.4% at 37 °C to 55.2% at 37 °C after 10 min). Reduced cell viability with the nanosystem was also dose and time dependant when compared to TMZ alone, which was only dose dependant. Furthermore, the effects of TMZ-MNP-FA NPs + RT + AMF were triple those of the NPs alone, and this triple modality (thermo-chemo-radiotherapy) achieved a 2.59-fold increase in cell death in C6 cells.
Basina et al. [134] synthesised Fe3O4 nanoparticles “decorated” with LAPONITE® nanodisks, a synthetic clay with diamagnetic properties. The hybrids exhibited differing sizes, while the zeta potential varied in a Fe3O4-content-dependant fashion, decreasing as iron content increased. Particles with 50 wt% iron content were found to be the most efficient at inducing hyperthermia, with the highest specific absorption rate (SAR) at least 1.5 times higher than hybrids with other iron concentrations (540 W/g @ 150 kHz). The 50 wt% hybrids exhibited a mean size of 202.6 nm and a zeta potential of −31.6 mV, achieving good colloidal stability in water. In vitro incubation with human glioblastoma (U87-EGFRvIII) and human fibroblast (HFF1) showed no difference in cell survival or proliferation compared to the negative control. Exposure of the hybrid to a 150 kHz AMF after 24 h incubation resulted in a large drop in cell viability compared to the control in all cell types, including therapy-resistant glioblastoma variants U87-EGFRvIII and U87-EGFR wildtype. In in vivo imaging studies, the hybrids were observed to cause a signal drop on MRI T2-weighted imaging and persisted in the rodent brain for 7 days after convection-enhanced delivery (CED). Further studies to evaluate therapeutic performance in vivo are necessary.

References

  1. Weishaupt, D.; Köchli, V.D.; Marincek, B. How Does MRI Work? 2nd ed.; Springer: Berlin/Heidelberg, Germany, 2006; ISBN 978-3-540-30067-0.
  2. Wirsching, H.G.; Galanis, E.; Weller, M. Glioblastoma. Handb. Clin. Neurol. 2016, 134, 381–397.
  3. Davis, M.E. Glioblastoma: Overview of Disease and Treatment. Clin. J. Oncol. Nurs. 2016, 20, S2–S8.
  4. Wen, P.Y.; Kesari, S. Malignant Gliomas in Adults. N. Engl. J. Med. 2008, 359, 492–507.
  5. Young, R.M.; Jamshidi, A.; Davis, G.; Sherman, J.H. Current Trends in the Surgical Management and Treatment of Adult Glioblastoma. Ann. Transl. Med. 2015, 3, 121.
  6. Caivano, R.; Lotumolo, A.; Rabasco, P.; Zandolino, A.; D’antuono, F.; Villonio, A.; Lancellotti, M.I.; Macarini, L.; Cammarota, A. 3 Tesla Magnetic Resonance Spectroscopy: Cerebral Gliomas vs. Metastatic Brain Tumors. Our Experience and Review of the Literature. Int. J. Neurosci. 2013, 123, 537–543.
  7. Das, B.K. Positron Emission Tomography: An Overview. In Positron Emission Tomography; Springer India: New Delhi, India, 2015; pp. 1–6. ISBN 978-81-322-2098-5.
  8. Drake, L.R.; Hillmer, A.T.; Cai, Z. Approaches to PET Imaging of Glioblastoma. Molecules 2020, 25, 568.
  9. Bailey, D.L.; Karp, J.S.; Surti, S. Physics and Instrumentation in PET. In Positron Emission Tomography; Springer: London, UK, 2005; pp. 13–39.
  10. Bailey, D.L. Data Acquisition and Performance Characterization in PET. In Positron Emission Tomography; Springer: London, UK, 2005; pp. 41–62. ISBN 978-1-84628-007-8.
  11. Götz, I.; Grosu, A.L. FET-PET Imaging for Treatment and Response Monitoring of Radiation Therapy in Malignant Glioma Patients—A Review. Front. Oncol. 2013, 3.
  12. Lohmann, P.; Stavrinou, P.; Lipke, K.; Bauer, E.K.; Ceccon, G.; Werner, J.-M.; Neumaier, B.; Fink, G.R.; Shah, N.J.; Langen, K.-J.; et al. FET PET Reveals Considerable Spatial Differences in Tumour Burden Compared to Conventional MRI in Newly Diagnosed Glioblastoma. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 591–602.
  13. Bashir, A.; Mathilde Jacobsen, S.; Mølby Henriksen, O.; Broholm, H.; Urup, T.; Grunnet, K.; Andrée Larsen, V.; Møller, S.; Skjøth-Rasmussen, J.; Skovgaard Poulsen, H.; et al. Recurrent Glioblastoma versus Late Posttreatment Changes: Diagnostic Accuracy of O-(2-Fluoroethyl)-L-Tyrosine Positron Emission Tomography (18F-FET PET). Neuro Oncol. 2019, 21, 1595–1606.
  14. Lohmann, P.; Elahmadawy, M.A.; Gutsche, R.; Werner, J.-M.; Bauer, E.K.; Ceccon, G.; Kocher, M.; Lerche, C.W.; Rapp, M.; Fink, G.R.; et al. FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation. Cancers 2020, 12, 3835.
  15. Poulsen, S.H.; Urup, T.; Grunnet, K.; Christensen, I.J.; Larsen, V.A.; Jensen, M.L.; af Rosenschöld, P.M.; Poulsen, H.S.; Law, I. The Prognostic Value of FET PET at Radiotherapy Planning in Newly Diagnosed Glioblastoma. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 373–381.
  16. Carles, M.; Popp, I.; Starke, M.M.; Mix, M.; Urbach, H.; Schimek-Jasch, T.; Eckert, F.; Niyazi, M.; Baltas, D.; Grosu, A.L. FET-PET Radiomics in Recurrent Glioblastoma: Prognostic Value for Outcome after Re-Irradiation? Radiat. Oncol. 2021, 16, 46.
  17. Muoio, B.; Giovanella, L.; Treglia, G. Recent Developments of 18F-FET PET in Neuro-Oncology. Curr. Med. Chem. 2017, 25, 3061–3073.
  18. Bisdas, S.; Ritz, R.; Bender, B.; Braun, C.; Pfannenberg, C.; Reimold, M.; Naegele, T.; Ernemann, U. Metabolic Mapping of Gliomas Using Hybrid MR-PET Imaging. Investig. Radiol. 2013, 48, 295–301.
  19. Song, S.; Cheng, Y.; Ma, J.; Wang, L.; Dong, C.; Wei, Y.; Xu, G.; An, Y.; Qi, Z.; Lin, Q.; et al. Simultaneous FET-PET and Contrast-Enhanced MRI Based on Hybrid PET/MR Improves Delineation of Tumor Spatial Biodistribution in Gliomas: A Biopsy Validation Study. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 1458–1467.
  20. Tatekawa, H.; Hagiwara, A.; Uetani, H.; Yao, J.; Oughourlian, T.C.; Bahri, S.; Wang, C.; Raymond, C.; Lai, A.; Cloughesy, T.F.; et al. Multiparametric MR-PET Measurements in Hypermetabolic Regions Reflect Differences in Molecular Status and Tumor Grade in Treatment-Naïve Diffuse Gliomas. J. Neurooncol. 2020, 149, 337–346.
  21. Chen, Z.; Jamadar, S.D.; Li, S.; Sforazzini, F.; Baran, J.; Ferris, N.; Shah, N.J.; Egan, G.F. From Simultaneous to Synergistic MR-PET Brain Imaging: A Review of Hybrid MR-PET Imaging Methodologies. Hum. Brain Mapp. 2018, 39, 5126–5144.
  22. Chaudhry, A.; Badie, B.; Jandial, R.; Chen, M.; Korn, R.; Rahmanuddin, S. Utility of Functional MRI and 3D Tractography in Presurgical Planning in Patients with Glioblastoma. Clin. Med. Image Libr. 2018, 4, 7–8.
  23. Caras, A.; Mugge, L.; Miller, W.K.; Mansour, T.R.; Schroeder, J.; Medhkour, A. Usefulness and Impact of Intraoperative Imaging for Glioma Resection on Patient Outcome and Extent of Resection: A Systematic Review and Meta-Analysis. World Neurosurg. 2020, 134, 98–110.
  24. Essayed, W.I.; Zhang, F.; Unadkat, P.; Cosgrove, G.R.; Golby, A.J.; O’Donnell, L.J. White Matter Tractography for Neurosurgical Planning: A Topography-Based Review of the Current State of the Art. Neuroimage Clin. 2017, 15, 659–672.
  25. Panesar, S.S.; Abhinav, K.; Yeh, F.C.; Jacquesson, T.; Collins, M.; Fernandez-Miranda, J. Tractography for Surgical Neuro-Oncology Planning: Towards a Gold Standard. Neurotherapeutics 2019, 16, 36–51.
  26. Fernandes, C.; Costa, A.; Osório, L.; Lago, R.C.; Linhares, P.; Carvalho, B.; Caeiro, C. Current Standards of Care in Glioblastoma Therapy; Codon Publications: Brisbane, QLD, Australia, 2017; ISBN 978-0-9944381-2-6.
  27. Manrique-Guzmán, S.; Herrada-Pineda, T.; Revilla-Pacheco, F. Surgical Management of Glioblastoma. Glioblastoma 2017, 243–261.
  28. Esteves, S.; Alves, M.; Castel-Branco, M.; Stummer, W. A Pilot Cost-Effectiveness Analysis of Treatments in Newly Diagnosed High-Grade Gliomas: The Example of 5-Aminolevulinic Acid Compared with White-Light Surgery. Neurosurgery 2015, 76, 552–562.
  29. Stummer, W.; Pichlmeier, U.; Meinel, T.; Wiestler, O.D.; Zanella, F.; Reulen, H.J. Fluorescence-Guided Surgery with 5-Aminolevulinic Acid for Resection of Malignant Glioma: A Randomised Controlled Multicentre Phase III Trial. Lancet Oncol. 2006, 7, 392–401.
  30. Jenkinson, M.D.; Barone, D.G.; Bryant, A.; Vale, L.; Bulbeck, H.; Lawrie, T.A.; Hart, M.G.; Watts, C. Intraoperative Imaging Technology to Maximise Extent of Resection for Glioma. Cochrane Database Syst. Rev. 2018, 2018.
  31. Kubben, P.L.; ter Meulen, K.J.; Schijns, O.E.M.G.; ter Laak-Poort, M.P.; van Overbeeke, J.J.; van Santbrink, H. Intraoperative MRI-Guided Resection of Glioblastoma Multiforme: A Systematic Review. Lancet Oncol. 2011, 12, 1062–1070.
  32. Golub, D.; Hyde, J.; Dogra, S.; Nicholson, J.; Kirkwood, K.A.; Gohel, P.; Loftus, S.; Schwartz, T.H. Intraoperative MRI versus 5-ALA in High-Grade Glioma Resection: A Network Meta-Analysis. J. Neurosurg. 2021, 134, 484–498.
  33. Coburger, J.; Wirtz, C.R. Fluorescence Guided Surgery by 5-ALA and Intraoperative MRI in High Grade Glioma: A Systematic Review. J. Neurooncol. 2019, 141, 533–546.
  34. Gessler, F.; Forster, M.T.; Duetzmann, S.; Mittelbronn, M.; Hattingen, E.; Franz, K.; Seifert, V.; Senft, C. Combination of Intraoperative Magnetic Resonance Imaging and Intraoperative Fluorescence to Enhance the Resection of Contrast Enhancing Gliomas. Neurosurgery 2015, 77, 16–22.
  35. Coburger, J.; Hagel, V.; Wirtz, C.R.; König, R. Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival. PLoS ONE 2015, 10, e0154756.
  36. Thust, S.C.; van den Bent, M.J.; Smits, M. Pseudoprogression of Brain Tumors. J. Magn. Reson. Imaging 2018, 48, 571–589.
  37. Strauss, S.B.; Meng, A.; Ebani, E.J.; Chiang, G.C. Imaging Glioblastoma Posttreatment. Neuroimaging Clin. N. Am. 2021, 31, 103–120.
  38. Young, R.J.; Gupta, A.; Shah, A.D.; Graber, J.J.; Chan, T.A.; Zhang, Z.; Shi, W.; Beal, K.; Omuro, A.M. MRI Perfusion in Determining Pseudoprogression in Patients with Glioblastoma. Clin. Imaging 2013, 37, 41–49.
  39. Le Fèvre, C.; Lhermitte, B.; Ahle, G.; Chambrelant, I.; Cebula, H.; Antoni, D.; Keller, A.; Schott, R.; Thiery, A.; Constans, J.-M.; et al. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: Part 1—Molecular, morphological and clinical features. Crit. Rev. Oncol. Hematol. 2021, 157, 103188.
  40. Wen, P.Y.; Macdonald, D.R.; Reardon, D.A.; Cloughesy, T.F.; Sorensen, A.G.; Galanis, E.; DeGroot, J.; Wick, W.; Gilbert, M.R.; Lassman, A.B.; et al. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. J. Clin. Oncol. 2010, 28, 1963–1972.
  41. Ellingson, B.M.; Wen, P.Y.; Cloughesy, T.F. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics 2017, 14, 307–320.
  42. Chawla, S.; Bukhari, S.; Afridi, O.M.; Wang, S.; Yadav, S.K.; Akbari, H.; Verma, G.; Nath, K.; Haris, M.; Bagley, S.; et al. Metabolic and Physiologic Magnetic Resonance Imaging in Distinguishing True Progression from Pseudoprogression in Patients with Glioblastoma. NMR Biomed. 2022, 35.
  43. Sidibe, I.; Tensaouti, F.; Roques, M.; Cohen-Jonathan-Moyal, E.; Laprie, A. Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review. Biomedicines 2022, 10, 285.
  44. Le Fèvre, C.; Constans, J.-M.; Chambrelant, I.; Antoni, D.; Bund, C.; Leroy-Freschini, B.; Schott, R.; Cebula, H.; Noël, G. Pseudoprogression versus True Progression in Glioblastoma Patients: A Multiapproach Literature Review. Part 2—Radiological Features and Metric Markers. Crit. Rev. Oncol. Hematol. 2021, 159, 103230.
  45. Denora, N.; Lee, C.; Iacobazzi, R.M.; Choi, J.Y.; Song, I.H.; Yoo, J.S.; Piao, Y.; Lopalco, A.; Leonetti, F.; Lee, B.C.; et al. TSPO-Targeted NIR-Fluorescent Ultra-Small Iron Oxide Nanoparticles for Glioblastoma Imaging. Eur. J. Pharm. Sci. 2019, 139, 105047.
  46. Henderson, F.; Jones, E.; Denbigh, J.; Christie, L.; Chapman, R.; Hoyes, E.; Claude, E.; Williams, K.J.; Roncaroli, F.; McMahon, A. 3D DESI-MS Lipid Imaging in a Xenograft Model of Glioblastoma: A Proof of Principle. Sci. Rep. 2020, 10, 16512.
  47. Sun, Y.-Z.; Yan, L.-F.; Han, Y.; Nan, H.-Y.; Xiao, G.; Tian, Q.; Pu, W.-H.; Li, Z.-Y.; Wei, X.-C.; Wang, W.; et al. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T1-Weighted Contrast-Enhanced Imaging. BMC Med. Imaging 2021, 21, 17.
  48. Gerritsen, J.K.W.; Klimek, M.; Dirven, C.M.F.; de Hoop, E.O.; Wagemakers, M.; Rutten, G.J.M.; Kloet, A.; Hallaert, G.G.; Vincent, A.J.P.E. The SAFE-Trial: Safe Surgery for Glioblastoma Multiforme: Awake Craniotomy versus Surgery under General Anesthesia. Study Protocol for a Multicenter Prospective Randomized Controlled Trial. Contemp. Clin. Trials 2020, 88, 105876.
  49. Dimou, J.; Beland, B.; Kelly, J. Supramaximal Resection: A Systematic Review of Its Safety, Efficacy and Feasibility in Glioblastoma. J. Clin. Neurosci. 2020, 72, 328–334.
  50. Bettag, C.; Hussein, A.; Behme, D.; Maragkou, T.; Rohde, V.; Mielke, D. Endoscopic Fluorescence-Guided Resection Increases Radicality in Glioblastoma Surgery. Oper. Neurosurg. 2020, 18, 41–46.
  51. Weller, M.; Le Rhun, E.; Preusser, M.; Tonn, J.C.; Roth, P. How We Treat Glioblastoma. ESMO Open 2019, 4, e000520.
  52. Alifieris, C.; Trafalis, D.T. Glioblastoma Multiforme: Pathogenesis and Treatment. Pharm. Ther. 2015, 152, 63–82.
  53. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 2005, 352, 987–996.
  54. Zhang, H.; Wang, R.; Yu, Y.; Liu, J.; Luo, T.; Fan, F. Glioblastoma Treatment Modalities besides Surgery. J. Cancer 2019, 10, 4793–4806.
  55. Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; et al. Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial. Lancet Oncol. 2009, 10, 459–466.
  56. Lee, S.Y. Temozolomide Resistance in Glioblastoma Multiforme. Genes Dis. 2016, 3, 198–210.
  57. Rajaratnam, V.; Islam, M.M.; Yang, M.; Slaby, R.; Ramirez, H.M.; Mirza, S.P. Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. Cancers 2020, 12, 937.
  58. Rider, B.J. Carmustine. In xPharm: The Comprehensive Pharmacology Reference; Elsevier: Amsterdam, The Netherlands, 2007; pp. 1–4. ISBN 9780080552323.
  59. Chowdhary, S.A.; Ryken, T.; Newton, H.B. Survival Outcomes and Safety of Carmustine Wafers in the Treatment of High-Grade Gliomas: A Meta-Analysis. J. Neurooncol. 2015, 122, 367–382.
  60. Anjum, K.; Shagufta, B.I.; Abbas, S.Q.; Patel, S.; Khan, I.; Shah, S.A.A.; Akhter, N.; ul Hassan, S.S. Current Status and Future Therapeutic Perspectives of Glioblastoma Multiforme (GBM) Therapy: A Review. Biomed. Pharmacother. 2017, 92, 681–689.
  61. Bregy, A.; Shah, A.H.; Diaz, M.V.; Pierce, H.E.; Ames, P.L.; Diaz, D.; Komotar, R.J. The Role of Gliadel Wafers in the Treatment of High-Grade Gliomas. Expert. Rev. Anticancer. Ther. 2013, 13, 1453–1461.
  62. Champeaux, C.; Weller, J. Implantation of Carmustine Wafers (Gliadel®®) for High-Grade Glioma Treatment. A 9-Year Nationwide Retrospective Study. J. Neurooncol. 2020, 147, 159–169.
  63. Xiao, Z.Z.; Wang, Z.F.; Lan, T.; Huang, W.H.; Zhao, Y.H.; Ma, C.; Li, Z.Q. Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis. Front. Neurol. 2020, 11.
  64. Geraldo, L.H.M.; Garcia, C.; da Fonseca, A.C.C.; Dubois, L.G.F.; de Sampaio e Spohr, T.C.L.; Matias, D.; de Camargo Magalhães, E.S.; do Amaral, R.F.; da Rosa, B.G.; Grimaldi, I.; et al. Glioblastoma Therapy in the Age of Molecular Medicine. Trends Cancer 2019, 5, 46–65.
  65. Tan, A.C.; Ashley, D.M.; López, G.Y.; Malinzak, M.; Friedman, H.S.; Khasraw, M. Management of Glioblastoma: State of the Art and Future Directions. CA Cancer J. Clin. 2020, 70, 299–312.
  66. Mohile, N.A.; Messersmith, H.; Gatson, N.T.N.; Hottinger, A.F.; Lassman, A.B.; Morton, J.; Ney, D.; Nghiemphu, P.L.; Olar, A.; Olson, J.; et al. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro Oncol. 2022, 24, 358–383.
  67. Weller, M.; van den Bent, M.; Preusser, M.; le Rhun, E.; Tonn, J.C.; Minniti, G.; Bendszus, M.; Balana, C.; Chinot, O.; Dirven, L.; et al. EANO Guidelines on the Diagnosis and Treatment of Diffuse Gliomas of Adulthood. Nat. Rev. Clin. Oncol. 2021, 18, 170–186.
  68. Antunes, A.F.; Pereira, P.; Reis, C.; Rijo, P.; Reis, C. Nanosystems for Skin Delivery: From Drugs to Cosmetics. Curr. Drug Metab. 2017, 18, 412–425.
  69. Oliveira, A.; Simões, S.; Ascenso, A.; Reis, C.P. Therapeutic Advances in Wound Healing. J. Dermatol. Treat. 2022, 33, 2–22.
  70. Reis, C.P.; Martinho, N.; Rosado, C.; Fernandes, A.S.; Roberto, A. Design of Polymeric Nanoparticles and Its Applications as Drug Delivery Systems for Acne Treatment. Drug Dev. Ind. Pharm. 2014, 40, 409–417.
  71. Silva, C.O.; Petersen, S.B.; Reis, C.P.; Rijo, P.; Molpeceres, J.; Fernandes, A.S.; Gonçalves, O.; Gomes, A.C.; Correia, I.; Vorum, H.; et al. EGF Functionalized Polymer-Coated Gold Nanoparticles Promote EGF Photostability and EGFR Internalization for Photothermal Therapy. PLoS ONE 2016, 11, e0165419.
  72. Guo, Y.; Liu, R.; Zhou, L.; Zhao, H.; Lv, F.; Liu, L.; Huang, Y.; Zhang, H.W.; Yu, C.; Wang, S. Blood-Brain-Barrier Penetrable Thiolated Paclitaxel-Oligo (p-Phenylene Vinylene) Nanomedicine with Increased Drug Efficiency for Glioblastoma Treatment. Nano Today 2020, 35, 100969.
  73. Ferreira, N.N.; Granja, S.; Boni, F.I.; Prezotti, F.G.; Ferreira, L.M.B.; Cury, B.S.F.; Reis, R.M.; Baltazar, F.; Gremião, M.P.D. Modulating Chitosan-PLGA Nanoparticle Properties to Design a Co-Delivery Platform for Glioblastoma Therapy Intended for Nose-to-Brain Route. Drug Deliv. Transl. Res. 2020.
  74. Zheng, T.; Wang, W.; Ashley, J.; Zhang, M.; Feng, X.; Shen, J.; Sun, Y. Self-Assembly Protein Superstructures as a Powerful Chemodynamic Therapy Nanoagent for Glioblastoma Treatment. Nanomicro. Lett. 2020, 12.
  75. Saha, S.; Yakati, V.; Shankar, G.; Jaggarapu, M.M.C.S.; Moku, G.; Madhusudana, K.; Banerjee, R.; Ramkrishna, S.; Srinivas, R.; Chaudhuri, A. Amphetamine Decorated Cationic Lipid Nanoparticles Cross the Blood-Brain Barrier: Therapeutic Promise for Combating Glioblastoma. J. Mater. Chem. B 2020, 8, 4318–4330.
  76. Manju, C.A.; Jeena, K.; Ramachandran, R.; Manohar, M.; Ambily, A.M.; Sajesh, K.M.; Gowd, G.S.; Menon, K.; Pavithran, K.; Pillai, A.; et al. Intracranially Injectable Multi-SiRNA Nanomedicine for the Inhibition of Glioma Stem Cells. Neurooncol. Adv. 2021, 3.
  77. Li, R.; Wang, H.; Liang, Q.; Chen, L.; Ren, J. Radiotherapy for Glioblastoma: Clinical Issues and Nanotechnology Strategies. Biomater. Sci. 2022, 10, 892–908.
  78. Chédeville, A.L.; Madureira, P.A. The Role of Hypoxia in Glioblastoma Radiotherapy Resistance. Cancers 2021, 13, 542.
  79. Minniti, G.; Niyazi, M.; Alongi, F.; Navarria, P.; Belka, C. Current Status and Recent Advances in Reirradiation of Glioblastoma. Radiat. Oncol. 2021, 16.
  80. Wu, W.; Klockow, J.L.; Zhang, M.; Lafortune, F.; Chang, E.; Jin, L.; Wu, Y.; Daldrup-Link, H.E. Glioblastoma Multiforme (GBM): An Overview of Current Therapies and Mechanisms of Resistance. Pharm. Res. 2021, 171.
  81. Mann, J.; Ramakrishna, R.; Magge, R.; Wernicke, A.G. Advances in Radiotherapy for Glioblastoma. Front. Neurol. 2018, 8.
  82. Goff, K.M.; Zheng, C.; Alonso-Basanta, M. Proton Radiotherapy for Glioma and Glioblastoma. Chin. Clin. Oncol. 2022, 11, 46.
  83. Mohan, R.; Liu, A.Y.; Brown, P.D.; Mahajan, A.; Dinh, J.; Chung, C.; McAvoy, S.; McAleer, M.F.; Lin, S.H.; Li, J.; et al. Proton Therapy Reduces the Likelihood of High-Grade Radiation-Induced Lymphopenia in Glioblastoma Patients: Phase II Randomized Study of Protons vs. Photons. Neuro. Oncol. 2021, 23, 284–294.
  84. Brown, P.D.; Chung, C.; Liu, D.D.; McAvoy, S.; Grosshans, D.; al Feghali, K.; Mahajan, A.; Li, J.; McGovern, S.L.; McAleer, M.F.; et al. A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity-Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma. Neuro. Oncol. 2021, 23, 1337–1347.
  85. Jiapaer, S.; Furuta, T.; Tanaka, S.; Kitabayashi, T.; Nakada, M. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma. Neurol. Med. Chir. 2018, 58, 405–421.
  86. Zanders, E.D.; Svensson, F.; Bailey, D.S. Therapy for Glioblastoma: Is It Working? Drug. Discov. Today 2019, 24, 1193–1201.
  87. Adhikaree, J.; Moreno-Vicente, J.; Kaur, A.P.; Jackson, A.M.; Patel, P.M. Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. Cells 2020, 9, 263.
  88. McGranahan, T.; Therkelsen, K.E.; Ahmad, S.; Nagpal, S. Current State of Immunotherapy for Treatment of Glioblastoma. Curr. Treat. Options Oncol. 2019, 20, 24.
  89. Šamec, N.; Zottel, A.; Videtič Paska, A.; Jovčevska, I. Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma. Molecules 2020, 25, 490.
  90. Marenco-Hillembrand, L.; Wijesekera, O.; Suarez-Meade, P.; Mampre, D.; Jackson, C.; Peterson, J.; Trifiletti, D.; Hammack, J.; Ortiz, K.; Lesser, E.; et al. Trends in Glioblastoma: Outcomes over Time and Type of Intervention: A Systematic Evidence Based Analysis. J. Neurooncol. 2020, 147, 297–307.
  91. Cloughesy, T.F.; Brenner, A.; de Groot, J.F.; Butowski, N.A.; Zach, L.; Campian, J.L.; Ellingson, B.M.; Freedman, L.S.; Cohen, Y.C.; Lowenton-Spier, N.; et al. A Randomized Controlled Phase III Study of VB-111 Combined with Bevacizumab vs. Bevacizumab Monotherapy in Patients with Recurrent Glioblastoma (GLOBE). Neuro Oncol. 2020, 22, 705–717.
  92. Reardon, D.A.; Brandes, A.A.; Omuro, A.; Mulholland, P.; Lim, M.; Wick, A.; Baehring, J.; Ahluwalia, M.S.; Roth, P.; Bähr, O.; et al. Effect of Nivolumab vs. Bevacizumab in Patients with Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020, 6, 1003–1010.
  93. Haddad, A.F.; Young, J.S.; Aghi, M.K. Using Viral Vectors to Deliver Local Immunotherapy to Glioblastoma. Neurosurg. Focus 2021, 50, E4.
  94. Wang, H.; Chao, Y.; Zhao, H.; Zhou, X.; Zhang, F.; Zhang, Z.; Li, Z.; Pan, J.; Wang, J.; Chen, Q.; et al. Smart Nanomedicine to Enable Crossing Blood–Brain Barrier Delivery of Checkpoint Blockade Antibody for Immunotherapy of Glioma. ACS Nano 2022, 16, 664–674.
  95. Todo, T.; Ito, H.; Ino, Y.; Ohtsu, H.; Ota, Y.; Shibahara, J.; Tanaka, M. Intratumoral Oncolytic Herpes Virus G47∆ for Residual or Recurrent Glioblastoma: A Phase 2 Trial. Nat. Med. 2022, 28, 1630–1639.
  96. Stupp, R.; Wong, E.T.; Kanner, A.A.; Steinberg, D.; Engelhard, H.; Heidecke, V.; Kirson, E.D.; Taillibert, S.; Liebermann, F.; Dbalý, V.; et al. NovoTTF-100A versus Physician’s Choice Chemotherapy in Recurrent Glioblastoma: A Randomised Phase III Trial of a Novel Treatment Modality. Eur. J. Cancer 2012, 48, 2192–2202.
  97. Wenger, C.; Miranda, P.C.; Salvador, R.; Thielscher, A.; Bomzon, Z.; Giladi, M.; Mrugala, M.M.; Korshoej, A.R. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred from Computational Modeling. IEEE Rev. Biomed. Eng. 2018, 11, 195–207.
  98. Kirson, E.D.; Dbalý, V.; Tovaryš, F.; Vymazal, J.; Soustiel, J.F.; Itzhaki, A.; Mordechovich, D.; Steinberg-Shapira, S.; Gurvich, Z.; Schneiderman, R.; et al. Alternating Electric Fields Arrest Cell Proliferation in Animal Tumor Models and Human Brain Tumors. Proc. Natl. Acad. Sci. USA 2007, 104, 10152–10157.
  99. Lantos, J.; Young, R.J.; Miranda, P.C.; Wenger, C.; Wong, E.T. TTFields Therapy: Preclinical and Clinical Data, 2nd ed.; Elsevier: Amsterdam, The Netherlands, 2016; ISBN 9780128011683.
  100. Alphandéry, E. Glioblastoma Treatments: An Account of Recent Industrial Developments. Front. Pharm. 2018, 9, 1–31.
  101. Luo, C.; Xu, S.; Dai, G.; Xiao, Z.; Chen, L.; Liu, Z. Tumor Treating Fields for High-Grade Gliomas. Biomed. Pharmacother. 2020, 127, 110193.
  102. Wenger, C.; Giladi, M.; Bomzon, Z.; Salvador, R.; Basser, P.J.; Miranda, P.C. Modeling Tumor Treating Fields (TTFields) Application in Single Cells during Metaphase and Telophase. In Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Milan, Italy, 25–29 August 2015; pp. 6892–6895.
  103. Wenger, C.; Salvador, R.; Basser, P.J.; Miranda, P.C. Modeling Tumor Treating Fields (TTFields) Application within a Realistic Human Head Model. In Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Milan, Italy, 25–29 August 2015; pp. 2555–2558.
  104. Wenger, C.; Salvador, R.; Basser, P.J.; Miranda, P.C. Improving Tumor Treating Fields Treatment Efficacy in Patients with Glioblastoma Using Personalized Array Layouts. Int. J. Radiat. Oncol. Biol. Phys. 2016, 94, 1137–1143.
  105. Gentilal, N.; Salvador, R.; Miranda, P.C. Temperature Control in TTFields Therapy of GBM: Impact on the Duty Cycle and Tissue Temperature. Phys. Med. Biol. 2019, 64.
  106. Bastiancich, C.; da Silva, A.; Estève, M.-A. Photothermal Therapy for the Treatment of Glioblastoma: Potential and Preclinical Challenges. Front. Oncol. 2021, 10.
  107. Cramer, S.W.; Chen, C.C. Photodynamic Therapy for the Treatment of Glioblastoma. Front. Surg. 2020, 6, 100161.
  108. Gupta, R.; Sharma, D. Manganese-Doped Magnetic Nanoclusters for Hyperthermia and Photothermal Glioblastoma Therapy. ACS Appl. Nano Mater. 2020, 3, 2026–2037.
  109. Pivetta, T.P.; Botteon, C.E.A.; Ribeiro, P.A.; Marcato, P.D.; Raposo, M. Nanoparticle Systems for Cancer Phototherapy: An Overview. Nanomaterials 2021, 11, 3132.
  110. Amaral, M.; Charmier, A.J.; Afonso, R.A.; Catarino, J.; Faísca, P.; Carvalho, L.; Ascensão, L.; Coelho, J.M.P.; Manuela Gaspar, M.; Reis, C.P. Gold-Based Nanoplataform for the Treatment of Anaplastic Thyroid Carcinoma: A Step Forward. Cancers 2021, 13, 1242.
  111. Kumari, S.; Sharma, N.; Sahi, S.V. Advances in Cancer Therapeutics: Conventional Thermal Therapy to Nanotechnology-Based Photothermal Therapy. Pharmaceutics 2021, 13, 1174.
  112. Anand, S.; Chan, T.; Hasan, T.; Maytin, E. Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review). Pharmaceuticals 2021, 14, 447.
  113. Ferreira-Gonçalves, T.; Gaspar, M.M.; Coelho, J.M.P.; Marques, V.; Viana, A.S.; Ascensão, L.; Carvalho, L.; Rodrigues, C.M.P.; Ferreira, H.A.; Ferreira, D.; et al. The Role of Rosmarinic Acid on the Bioproduction of Gold Nanoparticles as Part of a Photothermal Approach for Breast Cancer Treatment. Biomolecules 2022, 12, 71.
  114. Ferreira-Gonçalves, T.; Iglesias-Mejuto, A.; Linhares, T.; Coelho, J.M.P.; Vieira, P.; Faísca, P.; Catarino, J.; Pinto, P.; Ferreira, D.; Ferreira, H.A.; et al. Biological Thermal Performance of Organic and Inorganic Aerogels as Patches for Photothermal Therapy. Gels 2022, 8, 485.
  115. Kamath, A.A.; Friedman, D.D.; Akbari, S.H.A.; Kim, A.H.; Tao, Y.; Luo, J.; Leuthardt, E.C. Glioblastoma Treated with Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy. Neurosurgery 2019, 84, 836–843.
  116. Patel, P.; Patel, N.v.; Danish, S.F. Intracranial MR-Guided Laser-Induced Thermal Therapy: Single-Center Experience with the Visualase Thermal Therapy System. J. Neurosurg. 2016, 125, 853–860.
  117. Munoz-Casabella, A.; Alvi, M.A.; Rahman, M.; Burns, T.C.; Brown, D.A. Laser Interstitial Thermal Therapy for Recurrent Glioblastoma: Pooled Analyses of Available Literature. World Neurosurg. 2021, 153, 91–97.e1.
  118. Montemurro, N.; Anania, Y.; Cagnazzo, F.; Perrini, P. Survival Outcomes in Patients with Recurrent Glioblastoma Treated with Laser Interstitial Thermal Therapy (LITT): A Systematic Review. Clin. Neurol. Neurosurg. 2020, 195, 105942.
  119. Fadel, H.A.; Haider, S.; Pawloski, J.A.; Zakaria, H.M.; Macki, M.; Bartlett, S.; Schultz, L.; Robin, A.M.; Kalkanis, S.N.; Lee, I.Y. Laser Interstitial Thermal Therapy for First-Line Treatment of Surgically Accessible Recurrent Glioblastoma: Outcomes Compared with a Surgical Cohort. Neurosurgery 2022, 91, 701–709.
  120. Kumthekar, P. A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients. Available online: https://clinicaltrials.gov/ct2/show/record/NCT03020017 (accessed on 28 November 2022).
  121. Bonan, N.F.; Ledezma, D.K.; Tovar, M.A.; Balakrishnan, P.B.; Fernandes, R. Anti-Fn14-Conjugated Prussian Blue Nanoparticles as a Targeted Photothermal Therapy Agent for Glioblastoma. Nanomaterials 2022, 12, 2645.
  122. Lopes, J.; Rodrigues, C.M.P.; Gaspar, M.M.; Reis, C.P. How to Treat Melanoma? The Current Status of Innovative Nanotechnological Strategies and the Role of Minimally Invasive Approaches like PTT and PDT. Pharmaceutics 2022, 14, 1817.
  123. Bartusik-Aebisher, D.; Żołyniak, A.; Barnaś, E.; Machorowska-Pieniążek, A.; Oleś, P.; Kawczyk-Krupka, A.; Aebisher, D. The Use of Photodynamic Therapy in the Treatment of Brain Tumors—A Review of the Literature. Molecules 2022, 27, 6847.
  124. Da Silva, B.A.; Nazarkovsky, M.; Padilla-Chavarría, I.; Alejandra, E.; Mendivelso, C.; de Mello, H.L.; Nogueira, C.D.S.C.; Dos, R.; Carvalho, S.; Cremona, M.; et al. Novel Scintillating Nanoparticles for Potential Application in Photodynamic Cancer Therapy. Pharmaceutics 2022, 14, 2258.
  125. Schipmann, S.; Müther, M.; Stögbauer, L.; Zimmer, S.; Brokinkel, B.; Holling, M.; Grauer, O.; Suero Molina, E.; Warneke, N.; Stummer, W. Combination of ALA-Induced Fluorescence-Guided Resection and Intraoperative Open Photodynamic Therapy for Recurrent Glioblastoma: Case Series on a Promising Dual Strategy for Local Tumor Control. J. Neurosurg. 2020, 134, 426–436.
  126. Maier-Hauff, K.; Rothe, R.; Scholz, R.; Gneveckow, U.; Wust, P.; Thiesen, B.; Feussner, A.; von Deimling, A.; Waldoefner, N.; Felix, R.; et al. Intracranial Thermotherapy Using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme. J. Neurooncol. 2007, 81, 53–60.
  127. Monnier, C.A.; Burnand, D.; Rothen-Rutishauser, B.; Lattuada, M.; Petri-Fink, A. Magnetoliposomes: Opportunities and Challenges. Eur. J. Nanomed. 2014, 6, 201–215.
  128. Lal, S.; Verma, J.; van Noorden, C.J.F. Nanoparticles for Hyperthermic Therapy: Synthesis Strategies and Applications in Glioblastoma. Int. J. Nanomed. 2014, 9, 2863.
  129. Grauer, O.; Jaber, M.; Hess, K.; Weckesser, M.; Schwindt, W.; Maring, S.; Wölfer, J.; Stummer, W. Combined Intracavitary Thermotherapy with Iron Oxide Nanoparticles and Radiotherapy as Local Treatment Modality in Recurrent Glioblastoma Patients. J. Neurooncol. 2019, 141, 83–94.
  130. Gupta, R.; Sharma, D. Evolution of Magnetic Hyperthermia for Glioblastoma Multiforme Therapy. ACS Chem. Neurosci. 2019, 10, 1157–1172.
  131. Mahmoudi, K.; Bouras, A.; Bozec, D.; Ivkov, R.; Hadjipanayis, C. Magnetic Hyperthermia Therapy for the Treatment of Glioblastoma: A Review of the Therapy’s History, Efficacy and Application in Humans. Int. J. Hyperth. 2018, 34, 1316–1328.
  132. Liu, X.; Zhang, Y.; Wang, Y.; Zhu, W.; Li, G.; Ma, X.; Zhang, Y.; Chen, S.; Tiwari, S.; Shi, K.; et al. Comprehensive Understanding of Magnetic Hyperthermia for Improving Antitumor Therapeutic Efficacy. Theranostics 2020, 10, 3793–3815.
  133. Minaei, S.E.; Khoei, S.; Khoee, S.; Mahdavi, S.R. Sensitization of Glioblastoma Cancer Cells to Radiotherapy and Magnetic Hyperthermia by Targeted Temozolomide-Loaded Magnetite Tri-Block Copolymer Nanoparticles as a Nanotheranostic Agent. Life Sci. 2022, 306, 120729.
  134. Basina, G.; Diamantopoulos, G.; Devlin, E.; Psycharis, V.; Alhassan, S.M.; Pissas, M.; Hadjipanayis, G.; Tomou, A.; Bouras, A.; Hadjipanayis, C.; et al. LAPONITE®® Nanodisk-“Decorated” Fe 3 O 4 Nanoparticles: A Biocompatible Nano-Hybrid with Ultrafast Magnetic Hyperthermia and MRI Contrast Agent Ability. J. Mater. Chem. B 2022, 10, 4935–4943.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback